Literature DB >> 29439831

Routine Invasive Versus Selective Invasive Strategy in Elderly Patients Older Than 75 Years With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Aakash Garg1, Lohit Garg2, Manyoo Agarwal3, Amit Rout4, Hitesh Raheja5, Sahil Agrawal6, Sunil V Rao7, Marc Cohen8.   

Abstract

OBJECTIVE: To evaluate outcomes of routine invasive strategy (RIS) compared with selective invasive strategy (SIS) in elderly patients older than 75 years with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
METHODS: We systematically searched databases for randomized controlled trials (RCTs) between January 1, 1990, and October 1, 2016, comparing RIS with SIS for elderly patients (age>75 years) with NSTE-ACS. Random effects meta-analysis was conducted to estimate odds ratio (OR) with 95% CIs for composite of death or myocardial infarction (MI), and individual end points of all-cause death, cardiovascular (CV) death, MI, revascularization, and major bleeding.
RESULTS: A total of 6 RCTs with 1887 patients were included in the final analysis. Compared with an SIS, RIS was associated with significantly decreased risk of the composite end point of death or MI (OR, 0.65; 95% CI, 0.51-0.83). Similarly, RIS led to a significant reduction in the risk of MI (OR, 0.51; 95% CI, 0.40-0.66) and need for revascularization (OR, 0.31; 95% CI, 0.11-0.91) compared with SIS. There were no significant differences between RIS and SIS in terms of all-cause death (OR, 0.85; 95% CI, 0.63-1.20), CV death (OR, 0.84; 95% CI, 0.61-1.15), and major bleeding (OR, 1.96; 95% CI, 0.97-3.97).
CONCLUSION: In elderly patients older than 75 years with NSTE-ACS, RIS is superior to SIS for the composite end point (death or MI), primarily driven by reduced risk of MI.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29439831     DOI: 10.1016/j.mayocp.2017.11.022

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

1.  Is the contemporary care of the older persons with acute coronary syndrome evidence-based?

Authors:  Greg B Mills; Hanna Ratcovich; Jennifer Adams-Hall; Benjamin Beska; Emma Kirkup; Daniell E Raharjo; Murugapathy Veerasamy; Chris Wilkinson; Vijay Kunadian
Journal:  Eur Heart J Open       Date:  2021-12-17

2.  Increased level of high-sensitivity cardiac Troponin T in a geriatric population is determined by comorbidities compared to age.

Authors:  Seyed Mahdi Sedighi; Patrick Prud'Homme; Ahmed Ghachem; Serge Lepage; Michel Nguyen; Tamas Fulop; Abdelouahed Khalil
Journal:  Int J Cardiol Heart Vasc       Date:  2019-03-08

3.  Non-ST elevation acute coronary syndromes; clinical landscape, management strategy and in-hospital outcomes: an age perspective.

Authors:  Zainab Atiyah Dakhil; Hasan Ali Farhan
Journal:  Egypt Heart J       Date:  2021-03-31

4.  The Rate of Coronary Angiography Refusal in Older Patients with Non-ST Elevation Acute Coronary Syndrome and Its Impact on All-Cause Mortality.

Authors:  Kudret Keskin; Gokhan Cetinkal; Ozgur Selim Ser; Serhat Sigirci; Ahmet Gurdal; Kadriye Kilickesmez
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-12-29

5.  Early invasive strategy in senior patients with non-ST-segment elevation myocardial infarction: is it cost-effective? - a decision-analytic model and value of information analysis.

Authors:  Julija Simpson; Mehdi Javanbakht; Luke Vale
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692

6.  Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?

Authors:  George Kassimis; Grigoris V Karamasis; Athanasios Katsikis; Joanna Abramik; Nestoras Kontogiannis; Matthaios Didagelos; Dimitrios Petroglou; Christodoulos E Papadopoulos; Leonidas Poulimenos; Vassilios Vassilikos; Ioannis Kanonidis; Tushar Raina; Antonios Ziakas
Journal:  Curr Cardiol Rev       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.